BlueRock Therapeutics Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership
TORONTO and CAMBRIDGE, Mass., Aug. 17, 2017. BlueRock Therapeutics, which is developing cell-based therapies designed to alter the course of degenerative disease, today announces the expansion of the company's presence in Toronto with a research, development and manufacturing site in the MaRS Discovery District. BlueRock has formalized its broad research collaboration with the Toronto-based McEwen Centre for Regenerative Medicine at University Health Network (UHN), as well as its manufacturing partnership with the Centre for Commercialization of Regenerative Medicine (CCRM). Additionally, Michael Scott, Ph.D., has been appointed by BlueRock as senior vice president of product development and Toronto operations.
“We are tremendously excited about our rapidly expanding presence in Toronto, and the addition of Dr. Scott. Our R&D model leverages collaborations with world-class stem cell and disease biology experts, and this UHN collaboration will allow us to work closely with leaders in the field to develop breakthrough cell therapies for patients suffering from heart failure. In addition, we have strengthened our strategic partnership with CCRM, which leverages not only their expertise, but also their new cGMP manufacturing facility to accelerate the buildout of BlueRock’s manufacturing capabilities.”
For the full press release click here